Skip to main content Back to Top


Deferoxamine Injection

Products Affected - Description

    • Desferal injection, Novartis, 500 mg, vial, 4 count, NDC 00078-0467-91

Reason for the Shortage

    • Apotex has deferoxamine injection available.
    • Fresenius Kabi has deferoxamine injection available.
    • Pfizer has deferoxamine injection available.
    • Novartis did not provide a reason for the shortage.

Available Products

    • Deferoxamine injection, Apotex, 2 gram, vial, 4 count, NDC 60505-6237-06
    • Deferoxamine injection, Apotex, 500 mg, vial, 4 count, NDC 60505-6236-06
    • Deferoxamine injection, Fresenius Kabi, 2 gram, vial, 1 count, NDC 63323-0599-30
    • Deferoxamine injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0597-10
    • Deferoxamine injection, Pfizer, 2 gram, vial, 4 count, NDC 00409-2337-25

Estimated Resupply Dates

    • Novartis has Desferal 500 mg vials on back order and the company estimates a release date of early-June 2024.


Updated May 20, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 7, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.